• August 20, 2008Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
• April 22, 2008Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
• April 18, 2008Launch of KIPRES Tablets 5mg
• March 3, 2008Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
• February 21, 2008Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
• January 30, 2008Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
• January 25, 2008KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
• December 26, 2007KYORIN Obtains Credit Rating from R&I
• October 12, 2007Discontinuation of Cooperation on Baynas Marketing for Treatment of Allergic Rhinitis by Kyorin Pharmaceutical Co.,Ltd. and Bayer Yakuhin,Ltd.
• October 2, 2007Launch of "KIPRES" Oral Granules 4mg
• September 26, 2007Merger between Kyorin Phamaceutical Co.,Ltd. and Nisshin Kyorin Pharmaceutical Co.,Ltd.
• July 31, 2007Marketing Approval for "KIPRES" Oral Granules 4mg
• April 28, 2006Kyorin Licensee Announces Decision to Stop Commercialization of Tequin
• March 10, 2006On the Transition to a Holding - Company Structure
• March 10, 2006On Kyorin Corporate Branding and the establishment of a New Corporate Mark & Logotype

1 2